BMY - Bristol-Myers Squibb Company

NYSE - NYSE Delayed Price. Currency in USD
51.76
+0.18 (+0.35%)
At close: 4:00PM EDT

52.25 +0.49 (0.95%)
After hours: 7:59PM EDT

Stock chart is not supported by your current browser
Previous Close51.58
Open51.48
Bid0.00 x 0
Ask0.00 x 0
Day's Range50.56 - 51.87
52 Week Range50.56 - 70.05
Volume14,309,569
Avg. Volume9,076,917
Market Cap84.629B
Beta1.04
PE Ratio (TTM)84.85
EPS (TTM)0.61
Earnings DateApr 26, 2018
Forward Dividend & Yield1.60 (2.72%)
Ex-Dividend DateN/A
1y Target Est61.35
Trade prices are not sourced from all markets
  • Business Wire5 hours ago

    European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma

    Bristol-Myers Squibb Company today announced that the European Commission has approved an every four-week Opdivo monotherapy dosing schedule of 480 mg infused over 60 minutes as an option for patients with advanced melanoma and previously treated renal cell carcinoma.

  • TheStreet.com6 hours ago

    Drug Maker Bristol-Myers Squibb Is Having a Bad Reaction to Selling

    In this daily bar chart of BMY, below, we can see a temporary upside breakout in late February that was reversed in a few weeks. The daily On-Balance-Volume (OBV) line peaked in the middle of February and turned lower signaling that sellers of BMY had become more aggressive. In this weekly bar chart of BMY, below, we went back five years to get a better perspective on things.

  • How Analysts Rate Bristol-Myers Squibb in 1Q18
    Market Realist10 hours ago

    How Analysts Rate Bristol-Myers Squibb in 1Q18

    Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18. Also, the earnings per share are expected at $0.85 for 1Q18. The revenue growth is expected to be driven by the prioritized brands including Opdivo, Empliciti, Eliquis, Orencia, Sprycel, and Yervoy, partially offset by lower sales of established brands.

  • Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX
    Zacks10 hours ago

    Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX

    Four pharma/biotech companies are set to release earnings report on Apr 26. Let's take a look into how the companies are placed ahead of the upcoming results.

  • Analysts Expect Bristol-Myers Squibb to Post Revenue Growth in 1Q18
    Market Realist11 hours ago

    Analysts Expect Bristol-Myers Squibb to Post Revenue Growth in 1Q18

    As discussed, Bristol-Myers Squibb (BMY) is expected to report growth of ~6.3% to $5.2 billion in its 1Q18 earnings on April 26. The above graph shows the quarterly revenues of Bristol-Myers Squibb since 1Q17 and analysts’ estimates for 1Q18. Nearly 45% of total revenues for Bristol-Myers Squibb come from international sales, so the company is exposed to currency risk.

  • Why Bristol-Myers (BMY) Might Surprise This Earnings Season
    Zacks12 hours ago

    Why Bristol-Myers (BMY) Might Surprise This Earnings Season

    Bristol-Myers (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?
    Market Realist13 hours ago

    What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?

    Headquartered in New York City, Bristol-Myers Squibb (BMY) is one of the leading American pharmaceutical companies. Bristol-Myers Squibb’s portfolio includes various cardiovascular products, neuroscience products, immunoscience products, oncology products, and virology products.

  • Cramer Remix: Navigating buying opportunities in tech amid a sell-off
    CNBCyesterday

    Cramer Remix: Navigating buying opportunities in tech amid a sell-off

    Jim Cramer explains why doing some buying in the midst of a sell-off could be a good opportunity for investors.

  • CNBCyesterday

    Cramer's lightning round: Wait for Take Two's earnings before buying

    It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. Spirit Aerosystems Holdings : "No, no, I don't want you to lock in your loss. Bristol-Myers Squibb BMY : "Bristol-Myers has sold off so much, so much, and yet when I'm finished with it, it sells at 16 times earnings and it only yields 3 percent.

  • Gilead Sciences Focuses on Its Liver Disease Portfolio
    Market Realistyesterday

    Gilead Sciences Focuses on Its Liver Disease Portfolio

    By mid-2018, Gilead Sciences (GILD) expects its share of the HCV (hepatitis C) market, where it competes with AbbVie (ABBV), Merck (MRK), and Bristol-Myers Squibb (BMY), to stabilize. This stabilization is anticipated despite rapidly declining drug prices and reducing treatment duration due to new and better therapies. While the company is not expecting any disruptive product launches in the HCV segment in the next few years, it expects gradually declining patient numbers to affect revenue. Liver disease research programs

  • Why Bristol-Myers Squibb Company’s (NYSE:BMY) ROE Of 8.23% Does Not Tell The Whole Story
    Simply Wall St.yesterday

    Why Bristol-Myers Squibb Company’s (NYSE:BMY) ROE Of 8.23% Does Not Tell The Whole Story

    Bristol-Myers Squibb Company (NYSE:BMY) delivered a less impressive 8.23% ROE over the past year, compared to the 11.00% return generated by its industry. Though BMY’s recent performance is underwhelming, itRead More...

  • Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18
    Market Realistyesterday

    Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18

    Johnson & Johnson (JNJ) reported 8.4% growth in operating revenues and a 4.2% positive impact of foreign exchange to $20.0 billion in 1Q18 as compared to revenues of $17.8 billion during 1Q17. Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.

  • Reuters2 days ago

    Amid drug price worries, earnings to test U.S. pharma, biotech shares

    Major U.S. pharmaceutical and biotechnology companies, whose shares have been laggards even in a sluggish market, face a litmus test in the corporate earnings season as investors already gun-shy over concerns about pressures on drug prices prepare to give a sharp eye for both hits and misses. As a group, pharmaceutical stocks in the S&P 500 are down about 4 percent so far this year, while S&P biotech stocks are off about 6 percent. Shares of Biogen Inc, Celgene Corp and Bristol-Myers Squibb Co are all down at least 14 percent this year.

  • Eli Lilly’s 1Q18 Estimates: Revenue Growth Expected
    Market Realist2 days ago

    Eli Lilly’s 1Q18 Estimates: Revenue Growth Expected

    Wall Street analysts expect an ~3.0% increase in Eli Lilly & Co.’s (LLY) 1Q18 revenues to $5.5 billion. Eli Lilly’s products are sold in more than 120 countries, and its international sales comprise ~45.0% of its total revenues. As a result, the company is exposed to currency risk, and foreign exchange is expected to have a positive impact on its overall revenues during 1Q18.

  • Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings
    Market Realist2 days ago

    Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings

    Eli Lilly & Co. (LLY) is a leading US-based pharmaceutical company with a product portfolio covering human health products and animal health products. Eli Lilly is set to release its 1Q18 earnings on April 24.

  • Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?
    Zacks2 days ago

    Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?

    Bristol-Myers (BMY) is scheduled to report Q1 earnings on Apr 26.

  • Aptevo executive Jane Gross jumped to a startup and landed in the C-Suite
    American City Business Journals5 days ago

    Aptevo executive Jane Gross jumped to a startup and landed in the C-Suite

    Jane Gross broke through the glass ceiling for women in biotech by going small.

  • Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
    Zacks5 days ago

    Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR

    Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.

  • Bristol-Myers' Opdivo Gets Priority Review for Lung Cancer
    Zacks6 days ago

    Bristol-Myers' Opdivo Gets Priority Review for Lung Cancer

    The FDA accepts Bristol-Myers Squibb's (BMY) supplemental Biologics License Application and grants priority review for the label expansion of Opdivo to treat patients with small cell lung cancer.

  • Cabometyx Could Be Exelixis’s Long-Term Growth Driver
    Market Realist7 days ago

    Cabometyx Could Be Exelixis’s Long-Term Growth Driver

    In March 2018, the FDA accepted Exelixis’s (EXEL) supplemental New Drug Application (or sNDA) for Cabometyx as a therapy for the treatment of individuals with advanced hepatocellular carcinoma (or HCC) who have previously undergone therapy. Exelixis’s sNDA was based on the results of its Phase 3 CELESTIAL trial. In October 2017, an independent data-monitoring committee recommended that Exelixis stop its CELESTIAL efficacy trial after a review of the second planned interim analysis, wherein Cabometyx demonstrated statistically significant and clinically meaningful progress in overall survival compared to the placebo in individuals who had already been treated for advanced HCC.

  • How Exelixis’s Cabomeytx and Cometriq Performed in 4Q17 and 2017
    Market Realist7 days ago

    How Exelixis’s Cabomeytx and Cometriq Performed in 4Q17 and 2017

    In 4Q17, Exelixis’s (EXEL) Cabometyx reported revenue of $90.4 million compared to $44.7 million in 4Q16, which reflected a ~102% rise on a YoY (year-over-year) basis. The FDA’s approval of the drug’s label expansion also boosted its revenue growth in 4Q17. In 2017, Cabometyx generated revenue of $324 million compared to $93.5 million in 2016.

  • Business Wire7 days ago

    U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority Review

    Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration  has accepted for priority review its supplemental Biologics License Application for Opdivo  to treat patients with small cell lung cancer whose disease has progressed after two or more prior lines of therapy.

  • EARNINGS: Philip Morris misses on revenue, selling fewer cigarettes in Saudi Arabia
    Yahoo Finance Video6 days ago

    EARNINGS: Philip Morris misses on revenue, selling fewer cigarettes in Saudi Arabia

    Yahoo Finance's Jared Blikre and Alexis Christoforous break down the latest market action.

  • Trader adding to this beaten pharma stock
    CNBC Videos7 days ago

    Trader adding to this beaten pharma stock

    Kari Firestone, Aureus Asset Management, discusses why she is adding to her position in Bristol-Myers.